AzurRx BioPharma, Inc. AZRX
At closeSep 22, 2021, 12:00 AM EDT
52-week range unavailable
- Market cap
- 34.38M
- Shares out
- 9.97M
- Forward P/E
- -0.93
- Volume
- 629.03K
- Open
- 3.38
- Previous close
- 3.45
- Day's range
- 3.38 – 3.66
- Beta
- 1.51
- Analysts
- Buy
- Price target
- 16.00 (+363.8%)
- Earnings date
- Nov 15, 2021
Key statistics
- Enterprise value
- 24.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -26.37M
- Total cash
- 8.07M
- Total debt
- 543.81K
- Return on equity
- -1271.87%
- Short % of float
- 0.17%
- 50-day average
- 4.94
- 200-day average
- 7.50
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 16.00
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 15, 2021
Expected Nov 15, 2021. Consensus EPS estimate -0.80.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2021 | Sep 1, 2021 | -0.79 | — | — | — |
| Aug 16, 2021 | Jun 1, 2021 | -0.80 | — | — | — |
| May 24, 2021 | Mar 1, 2021 | -0.70 | — | — | — |
| Mar 31, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Nov 16, 2020 | Sep 1, 2020 | -1.20 | — | — | — |
| Aug 14, 2020 | Jun 1, 2020 | -0.90 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 2, 2021 | HC Wainwright & Co. | main | — | Buy |
| Apr 1, 2021 | Roth Capital | main | — | Buy |
| Apr 1, 2021 | HC Wainwright & Co. | main | — | Buy |
| Feb 10, 2021 | HC Wainwright & Co. | main | — | Buy |
| Apr 1, 2020 | H.C. Wainwright | reit | — | Buy |
| Sep 26, 2019 | H.C. Wainwright | reit | — | Buy |
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- azurrx.com
News
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today 
3 Penny Stocks That Top Investors Buying Right Now 
46 Biggest Movers From Yesterday 
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M 
36 Stocks Moving In Tuesday's Mid-Day Session 
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma 
72 Biggest Movers From Yesterday 
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript 
AzurRx BioPharma Announces Reverse Merger With First Wave Bio 
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
Your note
Sign in to keep a note on AZRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORKOWSKI EDWARD J | Director | Stock Award(Grant) | Mar 9, 2020 | 423,453 |
| CASAMENTO CHARLES J | Director | Stock Gift | Mar 18, 2020 | 224,996 |
| DUPRET DANIEL | Officer | Stock Award(Grant) | Jul 11, 2018 | 15,000 |
| PELICAN PARTNERS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 29, 2017 | 1,727,800 |
| RIDDELL ALASTAIR | Director | Stock Award(Grant) | Mar 10, 2020 | 132,049 |
| ROSS EDMUND BURKE JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 30, 2018 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 0.31% | 292,409 | 2.40M | Jun 29, 2021 |
| Bank Of New York Mellon Corporation | 0.09% | 86,308 | 707.73K | Jun 29, 2021 |
| Geode Capital Management, LLC | 0.05% | 43,355 | 355.51K | Jun 29, 2021 |
| Renaissance Technologies, LLC | 0.02% | 17,323 | 142.05K | Jun 29, 2021 |
| Citadel Advisors LLC | 0.02% | 17,227 | 141.26K | Jun 29, 2021 |
| Parsons Capital Management, Inc. | 0.02% | 16,820 | 137.92K | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.23% | 210,413 | 1.73M | Jun 29, 2021 |
| Vanguard Extended Market Index Fund | 0.08% | 72,751 | 596.56K | Jun 29, 2021 |
| Fidelity Extended Market Index Fund | 0.03% | 30,693 | 166.91K | Jul 30, 2021 |
| Fidelity Series Total Market Index Fund | 0.01% | 6,734 | 36.62K | Jul 30, 2021 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.01% | 6,494 | 53.25K | Jun 29, 2021 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.01% | 6,092 | 33.13K | Jul 30, 2021 |